Nearly a million Chinese have already received two experimental anti-Covid vaccines produced by the China National Pharmaceutical Group (Sinopharm), the drugmaker said on Friday. Although the results on efficacy have not yet been published, the immunizations have received authorization from the Chinese government for emergency use.
According to the Beijing authorization, doses can be applied in cases considered urgent, such as employees and students who need to travel abroad or workers in essential sectors, such as doctors and nurses.
“In this context, our vaccines have been inoculated in almost a million people and we have not received any negative feedback or serious adverse relationships,” said Sinopharm President Liu Jingzhen.
The state laboratory leader said that none of the people who took the immunizer had contracted the Sars-CoV-2 coronavirus, even though “they have traveled to more than 150 countries”.
So far, the only scientifically released study on one of Sinopharm’s two vaccines, which has no specific name, was published on August 14 by the “Journal of the American Medical Association (Jama)” and found that, in the early stages, immunization was able to activate the body’s immune response in 320 volunteers.
China currently has four vaccine candidates against Covid-19 in phase 3 clinical trials – the last step – in studies being conducted around the world. Sinopharm’s two immunizations are also in this phase and tests are being carried out, in addition to China, in the United Arab Emirates, Argentina, Peru, Egypt and Jordan. .
*The article has been translated based on the content of Source link by https://www.terra.com.br/noticias/mundo/quase-1-milhao-de-chineses-tomaram-vacinas-anti-covid-da-sinopharm,7f1b8c725602605e624e312d3f959ef801q7zqul.html
. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!